![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 29
Zeitschriftenartikel
Müller, V.; Banys-Paluchowski, M.; Friedl, T. W. P.; Fasching, P. A.; Schneeweiss, A.; Hartkopf, A.; Wallwiener, D.; Rack, B.; Meier-Stiegen, F.; Huober, J.; Rübner, M.; Hoffmann, O.; Müller, L.; Janni, W.; Wimberger, P.; Jäger, B.; Pantel, K.; Riethdorf, S.; Harbeck, N. und Fehm, T.
(2021):
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
In: Esmo Open, Bd. 6, Nr. 6
Hack, C. C.; Haeberle, L.; Brucker, S. Y.; Janni, W.; Volz, B.; Loehberg, C. R.; Hartkopf, A. D.; Walter, C.-B.; Baake, G.; Fridman, A.; Malter, W.; Würstlein, R.; Harbeck, N.; Hoffmann, O.; Kuemmel, S.; Martin, B.; Thomssen, C.; Graf, H.; Wolf, C.; Lux, M. P.; Bayer, C. M.; Rauh, C.; Almstedt, K.; Gass, P.; Heindl, F.; Brodkorb, T.; Willer, L.; Lindner, C.; Kolberg, H-C; Krabisch, P.; Weigel, M.; Steinfeld-Birg, D.; Kohls, A.; Brucker, C.; Schulz, V.; Fischer, G.; Pelzer, V.; Rack, B.; Beckmann, M. W.; Fehm, T.; Rody, A.; Maass, N.; Hein, A.; Fasching, P. A. und Nabieva, N.
(2020):
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
In: Breast, Bd. 50: S. 11-18
Tzschaschel, M. L. J.; Rack, B.; Andergassen, U.; Friedl, T. W. P.; Schneeweiss, A.; Müller, V.; Tanja, F.; Pantel, K.; Gade, J.; Lorenz, R.; Rezai, M.; Tesch, H.; Soeling, U.; Polasik, A.; Alunni-Fabbroni, M.; Trapp, E. K.; Mahner, S.; Schindlbeck, C.; Lichtenegger, W.; Beckmann, M. W.; Fasching, P. A. und Janni, W.
(2017):
Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients Results from the adjuvant SUCCESS A trial.
In: Cancer Research, Bd. 77
Tzschaschel, M. L. J.; Rack, B.; Majunke, L.; Trapp, E. K.; Mahner, S.; Fasching, P. A.; Fehm, T.; Schneeweiss, A.; Friedl, T. W. P.; Polasik, A.; Janni, W. und Alunni-Fabbroni, M.
(2017):
Profiling miRNA in high risk postoperative early breast cancer patients to detect possible association to correlation with immune system antitumor response.
In: Cancer Research, Bd. 77
Polasik, A.; Schramm, A.; Friedl, T. W. P.; Rack, B.; Trapp, E.; Tzschaschel, M.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Janni, W. und Fehm, T.
(2017):
The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo-or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer.
In: Cancer Research, Bd. 77
Polasik, A.; Schramm, A.; Friedl, T. W. P.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Janni, W. und Fehm, T.
(2017):
DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer.
In: Cancer Research, Bd. 77
Janni, W.; Rack, B.; Häberle, L.; Friedl, T. W. P.; Tesch, H.; Lorenz, R.; Jäger, B.; Fehm, T.; Müller, V.; Schneeweiß, A.; Lichtenegger, W.; Blohmer, J.; Beckmann, M. W.; Scholz, C.; Pantel, K.; Trapp, E. und Fasching, P. A.
(2017):
Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis.
In: Cancer Research, Bd. 77
Fehm, T.; Meier-Stiegen, F.; Riethdorf, S.; Schramm, A.; Polasik, A.; Niederacher, D.; Rack, B.; Taran, F.-A.; Müller, V.; Janni, W. und Huober, J.
(2017):
DETECT V - Detection of the expression of estrogen receptor and human epidermal growth factor receptor 2 on circulating tumor cells from metastatic breast cancer patients.
In: Cancer Research, Bd. 77
Hein, A.; Rack, B.; Li, L.; Ekici, A. B.; Reis, A.; Lux, M. P.; Cunningham, J. M.; Rübner, M.; Fridley, B. L.; Schneeweiss, A.; Tesch, H.; Lichtenegger, W.; Fehm, T.; Heinrich, G.; Rezai, M.; Beckmann, M. W.; Janni, W.; Weinshilboum, R. M.; Wang, L.; Fasching, P. A. und Häberle, L.
(2017):
Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study.
In: Geburtshilfe und Frauenheilkunde, Bd. 77, Nr. 6: S. 651-659
Jäger, B. A. S.; Neugebauer, J.; Andergassen, U.; Melcher, C.; Schochter, F.; Mouarrawy, D.; Ziemendorff, G.; Clemens, M.; Abel, E. v.; Heinrich, G.; Schüller, K.; Schneeweiss, A.; Fasching, P.; Beckmann, M. W.; Scholz, Ch.; Friedl, T. W. P.; Friese, K.; Pantel, K.; Fehm, T.; Janni, W. und Rack, B.
(2017):
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
In: PLOS One 12(6), e0173593 [PDF, 1MB]
In: PLOS One 12(6), e0173593 [PDF, 1MB]
Tiefenthaller, A.; Brix, N.; Escudero, Pazos M.; Kost, B.; Rack, B.; Bodungen, V. von; Weissenbacher, T.; Würstlein, R.; Rühle, P.; Gaipl, U.; Harbeck, N.; Belka, C.; Scheithauer, H. und Lauber, K.
(2017):
Immunologische Aspekte der intraoperativen Radiotherapie beim Mammakarzinom nach brusterhaltender Operation.
In: Strahlentherapie und Onkologie, Bd. 193:
S72-S72
Janni, W.; Schramm, A.; Friedl, T. W. P.; Schochter, E.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P. A.; Taran, F.-A.; Hortkopf, A.; Schneeweiss, A.; Mueller, V.; Aktas, B.; Krawczyk, N.; Pantel, K. und Fehm, T.
(2016):
Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer.
In: Oncology Research and Treatment, Bd. 39: S. 47
Janning, M.; Müller, V; Vettorazzi, E.; Cubas-Cordova, M.; Gensch, V; Ben Batalla, I; Eulenburg, C. zu; Schem, C.; Fasching, P. A.; Schnappauf, B.; Karn, T.; Fehm, T.; Just, M.; Kühn, T.; Holms, F.; Overkamp, F.; Krabisch, P.; Rack, B.; Denkert, C.; Untch, M.; Tesch, H.; Rezai, M.; Kittel, K.; Pantel, K.; Bokemeyer, C.; Loibl, S.; Minckwitz, G. von und Loges, S.
(2016):
Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.
In: Oncology Research and Treatment, Bd. 39: S. 185
Janni, W.; Rack, B.; Fasching, P.; Haeberle, L.; Friedl, T.; Tesch, H.; Lorenz, R.; Neugebauer, J.; Koch, J.; Jaeger, B.; Fehm, T.; Mueller, V.; Schneeweiß, A.; Lichtenegger, W.; Beckmann, M.; Scholz, C.; Pantel, K. und Trapp, E.
(2016):
Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis - Results from the adjuvant SUCCESS A trial.
In: Cancer Research, Bd. 76
Tzschaschel, M.; Trapp, E.; Rack, B.; Messina, C.; Mueller, V.; Fehm, T.; Janni, W.; Loehberg, C.; Wimberger, P.; Kolberg, H.-C.; Uleer, C.; Brudler, O.; Sotiriou, C.; Pierga, J.-Y.; Piccart, M. und Ignatiadis, M.
(2016):
TREAT CTC: An innovative therapy approach to eliminate circulating tumor cells (CTCs).
In: Oncology Research and Treatment, Bd. 39: S. 55
Schramm, A.; Friedl, T.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Kümmel, S.; Gebauer, G.; Müller, L.; Janni, W. und Fehm, T.
(2016):
The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells.
In: Oncology Research and Treatment, Bd. 39: S. 46-47
Janni, W.; Harbeck, N.; Rack, B.; Augustin, D.; Jückstock, J.; Wischnik, A.; Annecke, K.; Scholz, C.; Huober, J.; Zwingers, T.; Friedl, T. W. P. und Kiechle, M.
(2016):
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.
In: British Journal of Cancer, Bd. 114, Nr. 8: S. 863-871
Schindlbeck, C.; Andergassen, U.; Jückstock, J.; Rack, B.; Janni, W. und Jeschke, U.
(2016):
Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets.
In: Journal of Cancer Research and Clinical Oncology, Bd. 142, Nr. 9: S. 1883-1895
Schröder, L.; Rack, B.; Sommer, H.; Koch, J. G.; Weissenbacher, T.; Janni, W.; Schneeweiss, A.; Rezai, M.; Lorenz, R.; Jäger, B.; Schramm, A.; Häberle, L.; Fasching, P. A.; Friedl, T. W. P.; Beckmann, M. W. und Scholz, C.
(2016):
Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.
In: Geburtshilfe und Frauenheilkunde, Bd. 76, Nr. 5: S. 542-550
Fasching, P. A.; Loibl, S.; Eidtmann, H.; Tesch, H.; Untch, M.; Hilfrich, J.; Schem, C.; Rezai, M.; Gerber, B.; Costa, S. D.; Blohmer, J. U.; Fehm, T. N.; Huober, J.; Liedtke, C.; Müller, V.; Nekljudova, V.; Weber, K.; Rack, B.; Rübner, M.; Wang, L.; Ingle, J. N.; Weinshilboum, R. M.; Minckwitz, G. von und Couch, F.
(2016):
BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study.
In: Cancer Research, Bd. 76
Benz, S. C.; Rabizadeh, S.; Cecchi, F.; Beckman, M. W.; Brucker, S. Y.; Hartmann, A.; Golovato, J.; Hembrough, T.; Janni, W.; Rack, B.; Sanborn, J. Z.; Schneeweiss, A.; Vaske, C. J.; Soon-Shiong, P. und Fasching, P. A.
(2016):
Integrating whole genome sequencing data with RNAseq, pathway analysis, and quantitative proteomics to determine prognosis after standard adjuvant treatment with trastuzumab and chemotherapy in primary breast cancer patients.
In: Cancer Research, Bd. 76
Ruddy, K. J.; Rack, B.; Schwitulla, J.; Lambrechts, D.; Haeberle, L.; Schramm, A.; Trapp, E.; Scholz, C.; Beutler, A. S.; Ginsburg, E.; Couch, F.; Partridge, A. H.; Wang, L.; Weinshilboum, R. M.; Janni, W.; Vachon, C. und Fasching, P.
(2016):
Genetic predictors of chemotherapy-related amenorrhea.
In: Cancer Research, Bd. 76
Janni, W.; Schramm, A.; Friedl, T. W. P.; Schochter, F.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Krawczyk, N.; Pantel, K. und Fehm, T.
(2016):
Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer.
In: Cancer Research, Bd. 76
Schwentner, L.; Harbeck, N.; Singer, S.; Eichler, M.; Rack, B.; Forstbauer, H.; Wischnik, A.; Scholz, C.; Fink, V.; Huober, J.; Fried, T.; Weissenbacher, T.; Härtl, K.; Kiechle, M. und Janni, W.
(2016):
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer Results from the prospective multi-center randomized Adebar trial.
In: Cancer Research, Bd. 76
Schramm, A.; Fried, T. W. P.; Huober, J.; Jäger, B.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pante, K.; Meier-Stiegen, F.; Wimberger, P.; Kümmel, S.; Gebauer, G.; Müller, L.; Janni, W. und Fehm, T.
(2016):
The DETECT study program - Personalized treatment in metastatic breast cancer based on circulating tumor cells.
In: Cancer Research, Bd. 76
Jaeger, B. A. S.; Jückstock, Julia K.; Andergassen, Ulrich; Salmen, J.; Schochter, F.; Fink, V.; Alunni-Fabbroni, Marianna; Rezai, M.; Beck, Th.; Beckmann, M. W.; Friese, K.; Friedl, T. W. P.; Janni, W. und Rack, B.
(2014):
Evaluation of Two Different Analytical Methods for Circulating Tumor Cell Detection in Peripheral Blood of Patients with Primary Breast Cancer.
In: BioMed Research International, Bd. 2014, 491459
[PDF, 1MB]
Freydanck, M. K.; Laubender, Rüdiger P.; Rack, B.; Schuhmacher, L.; Jeschke, Udo und Scholz, C.
(2012):
Two-marker Combinations for Preoperative Discrimination of Benign and Malignant Ovarian Masses.
In: Anticancer Research, Bd. 32, Nr. 5: S. 2003-2008
Janni, W.; Rack, B.; Gerber, B.; Bauerfeind, I.; Krause, A.; Dian, D.; Sommer, H. und Friese, K.
(2006):
Pregnancy-associated breast cancer - Special features in diagnosis and treatment.
In: Onkologie, Nr. 3: S. 107-112
[PDF, 58kB]
Schindlbeck, C.; Kampik, T.; Janni, W.; Rack, B.; Jeschke, U.; Krajewski, S.; Sommer, H. und Friese, K.
(2005):
Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas.
In: Breast Cancer Research
7
[PDF, 228kB]